CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRx announces the publication of positive study data for its Barostim therapy.
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.